Hcw biologics receives fda clearance to proceed with phase 1b clinical trial for immunotherapeutic hcw9218 for pancreatic cancer

Company cleared to proceed with first-in-human clinical trial to evaluate hcw9218, company's lead product candidate, in refractory, advanced/metastatic pancreatic cancer
HCWB Ratings Summary
HCWB Quant Ranking